|
|
| Line 3: |
Line 3: |
| | <StructureSection load='4yu7' size='340' side='right'caption='[[4yu7]], [[Resolution|resolution]] 1.65Å' scene=''> | | <StructureSection load='4yu7' size='340' side='right'caption='[[4yu7]], [[Resolution|resolution]] 1.65Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4yu7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Bothrops_pirajai Bothrops pirajai]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YU7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YU7 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4yu7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Bothrops_pirajai Bothrops pirajai]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YU7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4YU7 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DHC:CAFFEIC+ACID'>DHC</scene>, <scene name='pdbligand=PE4:2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL'>PE4</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DHC:CAFFEIC+ACID'>DHC</scene>, <scene name='pdbligand=PE4:2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL'>PE4</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4yu7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yu7 OCA], [http://pdbe.org/4yu7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4yu7 RCSB], [http://www.ebi.ac.uk/pdbsum/4yu7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4yu7 ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4yu7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yu7 OCA], [https://pdbe.org/4yu7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4yu7 RCSB], [https://www.ebi.ac.uk/pdbsum/4yu7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4yu7 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/PA2H1_BOTPI PA2H1_BOTPI]] Snake venom phospholipase A2 (PLA2) homolog that lacks enzymatic activity, but displays myotoxin and edema-inducing activities in vivo. In vitro neuromuscular activities have also been observed, but they are not found in vivo and can be explained by the destabilization of the muscle membrane by the toxin. The myotoxic activity is inhibited by rosmarinic acid (RA).<ref>PMID:7660366</ref> <ref>PMID:22205953</ref> | + | [https://www.uniprot.org/uniprot/PA2H1_BOTPI PA2H1_BOTPI] Snake venom phospholipase A2 (PLA2) homolog that lacks enzymatic activity, but displays myotoxin and edema-inducing activities in vivo. In vitro neuromuscular activities have also been observed, but they are not found in vivo and can be explained by the destabilization of the muscle membrane by the toxin. The myotoxic activity is inhibited by rosmarinic acid (RA).<ref>PMID:7660366</ref> <ref>PMID:22205953</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 18: |
Line 18: |
| | </div> | | </div> |
| | <div class="pdbe-citations 4yu7" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 4yu7" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Phospholipase A2 homolog|Phospholipase A2 homolog]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| Line 24: |
Line 27: |
| | [[Category: Bothrops pirajai]] | | [[Category: Bothrops pirajai]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Fernandes, C A.H]] | + | [[Category: Fernandes CAH]] |
| - | [[Category: Fontes, M R.M]] | + | [[Category: Fontes MRM]] |
| - | [[Category: Phospholipase a2 phospholipase a2-like bothrops snake venom inhibitor]]
| + | |
| - | [[Category: Toxin]]
| + | |
| Structural highlights
Function
PA2H1_BOTPI Snake venom phospholipase A2 (PLA2) homolog that lacks enzymatic activity, but displays myotoxin and edema-inducing activities in vivo. In vitro neuromuscular activities have also been observed, but they are not found in vivo and can be explained by the destabilization of the muscle membrane by the toxin. The myotoxic activity is inhibited by rosmarinic acid (RA).[1] [2]
Publication Abstract from PubMed
One of the main challenges in toxicology today is to develop therapeutic alternatives for the treatment of snake venom injuries that are not efficiently neutralized by conventional serum therapy. Venom phospholipases A2 (PLA2s) and PLA2-like proteins play a fundamental role in skeletal muscle necrosis, which can result in permanent sequelae and disability. This leads to economic and social problems, especially in developing countries. In this work, we performed structural and functional studies with Piratoxin-I, a Lys49-PLA2 from Bothropspirajai venom, complexed with two compounds present in several plants used in folk medicine against snakebites. These ligands partially neutralized the myotoxic activity of PrTX-I towards binding on the two independent sites of interaction between Lys49-PLA2 and muscle membrane. Our results corroborate the previously proposed mechanism of action of PLA2s-like and provide insights for the design of structure-based inhibitors that could prevent the permanent injuries caused by these proteins in snakebite victims.
Structural Basis for the Inhibition of a Phospholipase A2-Like Toxin by Caffeic and Aristolochic Acids.,Fernandes CA, Cardoso FF, Cavalcante WG, Soares AM, Dal-Pai M, Gallacci M, Fontes MR PLoS One. 2015 Jul 20;10(7):e0133370. doi: 10.1371/journal.pone.0133370., eCollection 2015. PMID:26192963[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Mancuso LC, Correa MM, Vieira CA, Cunha OA, Lachat JJ, de Araujo HS, Ownby CL, Giglio JR. Fractionation of Bothrops pirajai snake venom: isolation and characterization of piratoxin-I, a new myotoxic protein. Toxicon. 1995 May;33(5):615-26. PMID:7660366
- ↑ Dos Santos JI, Cardoso FF, Soares AM, Dal Pai Silva M, Gallacci M, Fontes MR. Structural and functional studies of a bothropic myotoxin complexed to rosmarinic acid: new insights into Lys49-PLA inhibition. PLoS One. 2011;6(12):e28521. Epub 2011 Dec 21. PMID:22205953 doi:10.1371/journal.pone.0028521
- ↑ Fernandes CA, Cardoso FF, Cavalcante WG, Soares AM, Dal-Pai M, Gallacci M, Fontes MR. Structural Basis for the Inhibition of a Phospholipase A2-Like Toxin by Caffeic and Aristolochic Acids. PLoS One. 2015 Jul 20;10(7):e0133370. doi: 10.1371/journal.pone.0133370., eCollection 2015. PMID:26192963 doi:http://dx.doi.org/10.1371/journal.pone.0133370
|
